NCT05360381 2023-08-08
HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
Shanghai Henlius Biotech
Biocity Biopharmaceutics Co., Ltd.
Shanghai East Hospital
Amphivena Therapeutics, Inc.